04Jun
Cannabis-Derived Ingredients in FDA-Regulated Products: More Questions than Answers at FDA’s May 2019 Public Hearing
As most folks with any interest in the burgeoning cannabidiol (CBD) industry likely know, on May 31, 2019, the Food and Drug Administration held a public hearing “to obtain scientific data and information about the safety, manufacturing, product...
By:
Mintz - Consumer Product Safety Viewpoints
Related
Effective February 20, 2020, the New York City Department of Buildings (DOB) expanded the requiremen...
Read More >
While COVID-19 caused a dramatic slowdown to the deal-making boom of the last several years, we expe...
Read More >
As 2019 draws to a close and millions of people contemplate their resolutions for the new year, USCI...
Read More >
PE activity in Western Europe may have dipped in 2019 but this is not the full picture. Buyout activ...
Read More >
Below is the Federal Policy team’s weekly preview, posted when Congress is in session. HEADLINES -...
Read More >
Processing delays for immigration cases have increased by 46 percent in the past two fiscal years an...
Read More >